Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2-N-hexadecanoylamino-4-nitrophenyl-O-beta-lactoside + H2O
N-(2-hydroxy-5-nitrophenyl)hexadecanamide + beta-lactose
4-methylumbelliferyl beta-D-glucoside + H2O
4-methylumbelliferone + beta-D-glucose
4-nitrophenyl alpha-D-glucoside + H2O
4-nitrophenol + alpha-D-glucose
4-nitrophenyl beta-D-glucoside + H2O
4-nitrophenol + beta-D-glucose
7-nitro-2,1,3-benzoxadiazole-pentanol + digalactosyldiacylglycerol
?
-
transglycosylation
-
-
?
alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc
alpha-L-fucosyl-(1->2)-ganglioside GM1a + H2O
?
-
isoform EGCase I exhibits 100% activity with this substrate
-
-
?
alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-Glc
beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc
beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + beta-D-Gal-(1->4)-Glc
beta-D-GalNAc-(1->3)-alpha-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + beta-D-GalNAc-(1->3)-alpha-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc
-
-
-
?
blood group A type 1 heptaglycosylceramide + H2O
?
-
-
-
-
?
blood group A type 2 heptaglycosylceramide + H2O
?
-
-
-
-
?
C6-7-nitro-2,1,3-benzoxadiazole-glucosylceramide + H2O
?
D-erythro-dihydrosphingosine + H2O
?
-
-
-
-
?
D-erythro-sphingosine + H2O
?
-
-
-
-
?
Forssman glycolipid + H2O
?
-
isoform EGCase I exhibits 25.2% activity with this substrate
-
-
?
Fucalpha(1->3)GalNAcalpha(1->3)[Fucalpha(1->2)]Galbeta(1->4)Glcbeta(1-1)ceramide + H2O
Fucalpha(1->3)GalNAcalpha(1->3)[Fucalpha(1->2)]Galbeta(1->4)Glc + ceramide
-
84% of the activity with galactosylcerebroside
-
?
Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galalpha(1-4)Galbeta(1-4)Glc + ceramide
-
i.e. Gb3Cer
-
-
?
Galalpha1-6Galalpha1-6Galbeta1-6Galbeta1-1'ceramide + H2O
ceramide + Galalpha1-6Galalpha1-6Gal
-
most rapidly hydrolyzed
-
-
?
Galalpha1-6Galbeta1-3-diacylglycerol + H2O
?
-
-
-
-
?
Galalpha1-6Galbeta1-6Galbeta1-1'ceramide + H2O
ceramide + Galalpha1-6Galbeta1-6Gal
-
-
-
-
?
Galbeta(1,3)GalNacbeta(1,4)Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNacbeta(1,4)Galbeta(1,4)Glc
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glc
Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,4)Glc
Galbeta(1,6)Galbeta(1,6)Galbeta-1,1'-ceramide + H2O
?
Galbeta(1,6)Galbeta(1,6)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,6)Galbeta(1,6)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + methanol
?
-
i.e. GM1
products may be attributed to GM-1 oligosaccharide II3NeuAcGgOse4 and methyl-GM-1 oligosaccharide methyl-II3NeuAcGgOse4
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide 4-nitrobenzo-2-oxy-1,3-diazole + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + 4-nitrobenzo-2-oxy-1,3-diazole ceramide
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide
Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-4)Glc + ceramide
Galbeta(1-6)Galbeta(1-6)Galbeta(1-1)ceramide + H2O
Galbeta(1-6)Galbeta(1-6)Gal + ceramide
-
i.e. neogalactosylceramide, 77% of the activity with lactosylceramide
-
?
Galbeta1-1'-ceramide + H2O
?
-
-
-
-
?
Galbeta1-6Galbeta1-1'-ceramide + H2O
?
-
highest transglycosylation efficiency
-
-
?
Galbeta1-6Galbeta1-1'ceramide + H2O
ceramide + Galbeta1-6Galbeta
-
-
-
-
?
Galbeta1-6Galbeta1-6Galbeta1-1'-ceramide + H2O
?
-
-
-
-
?
Galbeta1-6Galbeta1-6Galbeta1-1'-ceramide + H2O
ceramide + Galbeta1-6Galbeta1-6Gal
-
-
-
-
?
Galbeta1-6Galbeta1-6Galbeta1-6Galbeta1-1'-ceramide + H2O
?
-
-
-
-
?
GalNAcalpha(1,4)GalNAcbeta(1,4)GlcNAcbeta(1,3)Manbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + GalNAcalpha(1,4)GalNAcbeta(1,4)GlcNAcbeta(1,3)Manbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
GalNAcalpha(1-3)GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
GalNAcalpha(1-3)GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glc + ceramide
-
i.e. Gb5Cer
-
-
?
GalNAcbeta(1,3)Galalpha(1,4)Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + GalNAcbeta(1,3)Galalpha(1,4)Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glc + ceramide
GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide
-
i.e. Gg3Cer
-
-
?
ganglioside + H2O
?
-
-
-
-
?
ganglioside fucosyl-GM1 + H2O
?
-
100% hydrolyzed by EGCase I and 19% hydrolyzed by EGCase II
-
-
?
ganglioside Gb3Cer + H2O
?
-
isoform EGCase I exhibits 100% activity with this substrate
-
-
?
ganglioside Gb4Cer + H2O
?
-
isoform EGCase I exhibits 33.9% activity with this substrate
-
-
?
ganglioside GbOse3Cer + H2O
?
-
73% hydrolyzed by EGCase I and 24% hydrolyzed by EGCase II
-
-
?
ganglioside GbOse4Cer + H2O
?
-
34% hydrolyzed by EGCase I and 7% hydrolyzed by EGCase II
-
-
?
ganglioside GbOse5Cer + H2O
?
-
25% hydrolyzed by EGCase I and 6.5% hydrolyzed by EGCase II
-
-
?
ganglioside GM1a + H2O
?
-
isoform EGCase I exhibits 100% activity with this substrate
-
-
?
ganglioside GM3 + H2O
?
-
isoform EGCase I exhibits 100% activity with this substrate
-
-
?
ganglioside TGC + H2O
?
-
66% hydrolyzed by EGCase III
-
-
?
GlcA4Me-beta(1,4)[GalNAc-Me-alpha(1,3)]Fucalpha(1,4)GlcNAcbeta(1,2)Manalpha(1,3)[Xylbeta(1,2)]Manbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + GlcA4Me-beta(1,4)[GalNAc-Me-alpha(1,3)]Fucalpha(1,4)GlcNAcbeta(1,2)Manalpha(1,3)[Xylbeta(1,2)]Manbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Glcbeta1-6Galbeta1-1'-ceramide + H2O
?
-
-
-
-
?
GlcNAcalpha1-2Fucalpha1-3Manbeta1-4Glcbeta1-1'-ceramide + H2O
ceramide + GlcNAcalpha1-2Fucalpha1-3Manbeta1-4Glc
-
-
-
-
?
GlcNAcbeta(1-2)Manalpha(1-3)Manbeta(1-4)Glcbeta(1-1)ceramide + H2O
GlcNAcbeta(1-2)Manalpha(1-3)Manbeta(1-4)Glc + ceramide
-
35% of the activity with lactosylceramide
-
?
globotetraosylceramide + H2O
?
-
-
-
-
?
globotriaosylceramide + H2O
?
-
-
-
-
?
glucosylceramide + H2O
?
-
isoform EGCase I exhibits 6.7% activity with this substrate
-
-
?
glycosphingolipid + H2O
?
GM1 ganglioside + H2O
GM1-aglycan + beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc
-
-
-
?
isoglobotetraosylceramide + H2O
?
-
-
-
-
?
isoglobotriaosylceramide + H2O
?
-
-
-
-
?
lactosylceramide + H2O
?
-
isoform EGCase I exhibits 29.9% activity with this substrate
-
-
?
Manalpha(1-3)Manbeta(1-4)Glcbeta(1-1)ceramide + H2O
Manalpha(1-3)Manbeta(1-4)Glc + ceramide
-
88% of the activity with lactosylceramide
-
?
Manbeta(1-4)Glcbeta(1-1)ceramide + H2O
Manbeta(1-4)Glc + ceramide
-
93% of the activity with lactosylceramide
-
?
monogalactosylceramide + H2O
ceramide + D-galactose
-
-
-
-
?
NeuAcalpha(2,3)Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + NeuAcalpha(2,3)Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
NeuAcalpha(2,3)Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + NeuAcalpha(2,3)Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha-2,3]Gal-beta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100, most favoured substrate
-
-
?
NeuAcalpha(2,3)Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + NeuAcalpha(2,3)Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc + ceramide
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
GT, 81% of the activity with lactosylceramide
-
?
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide
non-acid glycosphingolipids of human gastric epithelium + H2O
?
-
-
-
-
?
oligoglycosylglucosyl-(1<->1)-ceramide + H2O
ceramide + oligoglycosylglucose
-
-
-
-
?
porcine brain ganglioside-1 + H2O
?
-
-
-
-
?
porcine brain ganglioside-3 + H2O
?
-
-
-
-
?
porcine brain ganglioside-4 + H2O
?
-
-
-
-
?
porcine brain ganglioside-5 + H2O
?
-
-
-
-
?
resorufin + beta-D-glucose + H2O
resorufin-beta-D-glucoside
trigalactosylceramide + H2O
?
-
-
-
-
?
additional information
?
-
2-N-hexadecanoylamino-4-nitrophenyl-O-beta-lactoside + H2O
N-(2-hydroxy-5-nitrophenyl)hexadecanamide + beta-lactose
-
-
-
-
?
2-N-hexadecanoylamino-4-nitrophenyl-O-beta-lactoside + H2O
N-(2-hydroxy-5-nitrophenyl)hexadecanamide + beta-lactose
-
derivative possessing an N-acyl chain, 4-nitrophenyllactoside chromogenic substrate C16ampNPLac
-
-
?
4-methylumbelliferyl beta-D-glucoside + H2O
4-methylumbelliferone + beta-D-glucose
-
-
-
-
?
4-methylumbelliferyl beta-D-glucoside + H2O
4-methylumbelliferone + beta-D-glucose
-
-
-
-
?
4-nitrophenyl alpha-D-glucoside + H2O
4-nitrophenol + alpha-D-glucose
-
low activity
-
-
?
4-nitrophenyl alpha-D-glucoside + H2O
4-nitrophenol + alpha-D-glucose
-
low activity
-
-
?
4-nitrophenyl beta-D-glucoside + H2O
4-nitrophenol + beta-D-glucose
-
high activity
-
-
?
4-nitrophenyl beta-D-glucoside + H2O
4-nitrophenol + beta-D-glucose
-
high activity
-
-
?
alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc
-
-
-
?
alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc
-
-
-
?
alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-Glc
-
-
-
?
alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-Glc
-
-
-
?
alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-Glc
preferred substrate
-
-
?
beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc
-
-
-
?
beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc
-
-
-
?
beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc
-
-
-
?
beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + beta-D-Gal-(1->4)-Glc
-
-
-
?
beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + beta-D-Gal-(1->4)-Glc
-
-
-
?
beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide + H2O
ceramide + beta-D-Gal-(1->4)-Glc
-
-
-
?
C6-7-nitro-2,1,3-benzoxadiazole-glucosylceramide + H2O
?
-
-
-
-
?
C6-7-nitro-2,1,3-benzoxadiazole-glucosylceramide + H2O
?
-
-
-
-
?
Galbeta(1,3)GalNacbeta(1,4)Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNacbeta(1,4)Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNacbeta(1,4)Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNacbeta(1,4)Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
Aiptasia sp.
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
Cellana sp.
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
Entacmaea sp.
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
Marphysa sp.
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
Meretrix sp.
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,3)]Galbeta(1,4)Glc
Ruditapes sp.
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,3)GalNAcbeta(1,4)[NeuAcalpha(2,8)NeuAcalpha(2,3)]Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,4)Glcbeta-1,1'-ceramide + H2O
ceramide + Galbeta(1,4)Glc
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100
-
-
?
Galbeta(1,6)Galbeta(1,6)Galbeta-1,1'-ceramide + H2O
?
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100, no reaction
-
-
?
Galbeta(1,6)Galbeta(1,6)Galbeta-1,1'-ceramide + H2O
?
-
37°C, pH 3.0, 0.2% (w/v) Triton X-100, no reaction
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
Condylactis sp.
-
i.e. GM1
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
i.e. GM1
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
cholera toxin receptor
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
i.e. GM1
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
i.e. GM1
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
i.e. GM1
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
i.e. GM1
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
i.e. GM1
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
i.e. GM1
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
GM1a
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
GM1a
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
as active as lactosylceramide
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
i.e. GM1
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
i.e. GM1
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
as active as lactosylceramide
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide 4-nitrobenzo-2-oxy-1,3-diazole + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + 4-nitrobenzo-2-oxy-1,3-diazole ceramide
-
i.e. NBD-GM1
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide 4-nitrobenzo-2-oxy-1,3-diazole + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + 4-nitrobenzo-2-oxy-1,3-diazole ceramide
-
i.e. NBD-GM1
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
GD1b
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
GD1b
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
good substrate for strain M-777, weak substrate for strain C9
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
GD1b
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
good substrate for strain M-777, weak substrate for strain C9
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide
weak substrate
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide
i.e. asialo-GM1
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide
-
as active as lactosylceramide
-
?
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide
-
i.e. asialo-GM1
-
?
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide
-
i.e. asialo-GM1
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide
i.e. asialo-GM1
-
-
?
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-3)GalNAcbeta(1-4)Galbeta(1-4)Glc + ceramide
-
i.e. asialo-GM1
-
-
?
Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-4)Glc + ceramide
weak substrate
-
-
?
Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-4)Glc + ceramide
i.e. lactosylceramide
-
-
?
Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-4)Glc + ceramide
-
i.e. lactosylceramide
i.e. lactose
r
Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-4)Glc + ceramide
-
i.e. lactosylceramide
-
?
Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-4)Glc + ceramide
-
i.e. lactosylceramide
-
-
?
Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
Galbeta(1-4)Glc + ceramide
i.e. lactosylceramide
-
-
?
GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glc + ceramide
weak substrate
-
-
?
GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glc + ceramide
-
i.e. Gb4Cer
-
-
?
GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glc + ceramide
-
i.e. Gb4Cer
-
?
GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glc + ceramide
i.e. Gb4Cer
-
-
?
GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
-
-
-
?
GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
-
-
?
GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
GM2, 94% of the activity with lactosylceramide
-
?
ganglioside GD1a + H2O
?
-
isoform EGCase I exhibits 100% activity with this substrate
-
-
?
ganglioside GD1a + H2O
?
-
100% hydrolyzed by EGCase I and II
-
-
?
ganglioside GD1a + H2O
?
-
100% hydrolyzed by EGCase I and II
-
-
?
ganglioside GD1b + H2O
?
-
isoform EGCase I exhibits 100% activity with this substrate
-
-
?
ganglioside GD1b + H2O
?
-
87% hydrolyzed by EGCase I and 74% hydrolyzed by EGCase II
-
-
?
ganglioside GD1b + H2O
?
-
87% hydrolyzed by EGCase I and 74% hydrolyzed by EGCase II
-
-
?
ganglioside GD3 + H2O
?
-
isoform EGCase I exhibits 100% activity with this substrate
-
-
?
ganglioside GD3 + H2O
?
-
100% hydrolyzed by EGCase I and II
-
-
?
ganglioside GD3 + H2O
?
-
100% hydrolyzed by EGCase I and II
-
-
?
ganglioside GM1 + H2O
?
-
100% hydrolyzed by EGCase I and II
-
-
?
ganglioside GM1 + H2O
?
-
100% hydrolyzed by EGCase I and II
-
-
?
glycosphingolipid + H2O
?
-
glycosphingolipids readily hydrolyzed, globo-type (slowly)
-
-
?
glycosphingolipid + H2O
?
-
ganglio-type
-
-
?
glycosphingolipid + H2O
?
-
neutral and acidic in presence of 0.1% Triton X-100, lacto-type
-
-
?
glycosphingolipid + H2O
?
-
glycosphingolipids, overview
-
-
?
glycosphingolipid + H2O
?
-
strongly resistant to hydrolysis by endoglycoceramidase II in comparison with endoglycoceramidase I
-
-
?
glycosphingolipid + H2O
?
-
ganglio-type
-
-
?
glycosphingolipid + H2O
?
-
GM3
-
-
?
glycosphingolipid + H2O
?
-
neutral and acidic in presence of 0.1% Triton X-100, lacto-type
-
-
?
glycosphingolipid + H2O
?
-
GM2
-
-
?
glycosphingolipid + H2O
?
-
cell-surface glycosphingolipids of erythrocytes, horse-erythrocyte cell-surface GM3 and guinea pig erythrocyte cell-surface Gg3Cer
-
-
?
glycosphingolipid + H2O
?
-
release of glycans from the ceramide moieties of glycosphingolipids by endoglycoceramidase II treatment in order to analyze structures of glycosphingolipids in normal human colorectal epithelial cells, and characteristic alterations of oligosaccharide structures in malignant transformation
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
-
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
GD, 93% of the activity with lactosylceramide
-
?
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
GD1a
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
GD1a
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
GT1b
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
good substrate for strain M-777, weak substrate for strain C9
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
GT1b
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
GT1b
-
-
?
NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide
i.e. GM3
-
-
?
NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide
-
93% of the activity with lactosylceramide
-
?
NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide
-
i.e. GM3
-
?
NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide
-
i.e. GM3
-
-
?
NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide
i.e. GM3
-
-
?
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc + ceramide
-
-
-
-
?
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc + ceramide
-
-
-
-
?
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc + ceramide
-
-
-
?
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc + ceramide
-
i.e. sialylparagloboside, as active as lactosylceramide
-
?
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
GQ1b
-
-
?
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
-
-
?
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
good substrate for strain M-777, weak substrate for strain C9
-
-
?
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-8)NeuAcalpha(2-3))Galbeta(1-4)Glc + ceramide
-
GQ1b
-
-
?
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide
GD3
-
-
?
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O
NeuAcalpha(2-8)NeuAcalpha(2-3)Galbeta(1-4)Glc + ceramide
-
GD3
-
-
?
resorufin + beta-D-glucose + H2O
resorufin-beta-D-glucoside
-
highest catalytic efficiency
-
-
?
resorufin + beta-D-glucose + H2O
resorufin-beta-D-glucoside
-
highest catalytic efficiency
-
-
?
additional information
?
-
-
enzyme has transglycosylation activity, 1-hexanol is best acceptor for GM1, 1-pentanol and 1-heptanol are also used
-
-
?
additional information
?
-
-
enzyme prefers lactosides with acylamide structures over simple n-alkyl lactosides as substrates
-
-
?
additional information
?
-
-
enzyme destroys the cholera toxin receptor GM1 on the cell surface of HELA cells and therefore reduces the amount of cholera toxin attached to the cells
-
-
?
additional information
?
-
-
enzyme has transglycosylation activity, 1-hexanol is best acceptor for GM1, 1-pentanol and 1-heptanol are also used
-
-
?
additional information
?
-
-
does not hydrolyze ganglio-, globo-, or lacto-series glycosphingolipids
-
-
?
additional information
?
-
-
EGALC specifically hydrolyzes the Galbeta1-1'-ceramide linkage in 6-Gal series glycosphingolipids
-
-
?
additional information
?
-
-
no activity towards Galbeta1-6Glcbeta1-1'-ceramide, Galbeta1-4Galbeta1-1'-ceramide, Galalpha1-1'ceramide, Glcbeta1-1'-ceramide, Galbeta1-4Glcbeta1-1'ceramide, Galalpha1-4Galbeta1-4Glcbeta1-1'-ceramide, and Galbeta1-3GalNAcbeta1-4(NeuAcalpha2-3)Galbeta1-4Glcbeta1-1'-ceramide
-
-
?
additional information
?
-
-
almost no hydrolysis is observed for isoform EGCase II with alpha-L-fucosyl-(1->2)-ganglioside GM1a, ganglioside Gb3Cer, and ganglioside Gb4Cer. Isoform EGCase I shows no activity with ganglioside GM4, trigalactosylceramide, sulfatide, and sphingomyelin
-
-
?
additional information
?
-
-
for transglycosylation activity, isoform EGCase I prefers alkanols with a relatively long carbon chain such as pentanol and hexanol as an acceptor substrate
-
-
?
additional information
?
-
specifically hydrolyzes the glycosidic linkage between the oligosaccharide and the ceramide moieties of various glycosphingolipids. No activity with beta-D-Glc-(1<->1')-ceramide and beta-D-Gal-(1<->1')-ceramide
-
-
?
additional information
?
-
specifically hydrolyzes the glycosidic linkage between the oligosaccharide and the ceramide moieties of various glycosphingolipids. No activity with beta-D-Glc-(1<->1')-ceramide and beta-D-Gal-(1<->1')-ceramide
-
-
?
additional information
?
-
-
no substrate: GalNAcbeta(1-3)Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide, i.e. Gb4Cer
-
-
?
additional information
?
-
-
no substrate: sulfatides
-
-
?
additional information
?
-
-
no substrate: sphingomyelins
-
-
?
additional information
?
-
-
no substrate: gala-type glycosphingolipids
-
-
?
additional information
?
-
-
enzyme prefers lactosides with acylamide structures over simple n-alkyl lactosides as substrates
-
-
?
additional information
?
-
-
no substrate: cerebrosides
-
-
?
additional information
?
-
-
no substrate: glycoglycerolipids
-
-
?
additional information
?
-
-
no substrate: Galalpha(1-4)Galbeta(1-4)Glcbeta(1-1)ceramide + H2O, i.e. Gb3Cer
-
-
?
additional information
?
-
-
no substrate: N-linked glycoproteins
-
-
?
additional information
?
-
-
no substrate: O-linked glycoproteins
-
-
?
additional information
?
-
-
hardly attacks linkages between monosaccharides and ceramides, i.e. cerebrosides, or between oligosaccharides and diacylglycerol, i.e. glycoglycerolipids
-
-
?
additional information
?
-
-
enzyme from strain C9 hydrolyzes b-series gangliotetraosylceramides more slowly than M-777 enzyme, whereas both enzymes hydrolyse a-series gangliosides and neutral glycosphingolipids to the same extent
-
-
?
additional information
?
-
-
reduces glycosphingolipid levels in HL60 cells
-
-
?
additional information
?
-
-
removes glycosphinolipid-sugar chains from the cell surface of living cells
-
-
?
additional information
?
-
-
reduces ganglioside content in membrane fractions and intact cells of A431 cells
-
-
?
additional information
?
-
-
acidic glycosphingolipids from primary colonic adenocarcinoma and hepatic metastasis, releases glycans from the ceramide moiety
-
-
?
additional information
?
-
-
both rhodococcal EGCases I and II efficiently hydrolyze ganglio-series glycosphingolipids, whereas EGCase I hydrolyzes globo-series-glycosphingolipids much faster than EGCase II. The glycan chain from fucosyl-GM1 can be prepared by using EGCase I. EGCase III stands alone to hydrolyze 6-gala-series glycosphingolipids. All EGCases are not able to hydrolyze sphingomyelin and sulfatide
-
-
?
additional information
?
-
-
synthesis of sugar-sphingolipid glycosidic linkages. Extent of ganglioside synthesis is proportional to enzyme concentration and length of incubation time
-
-
?
additional information
?
-
-
enzyme from strain C9 hydrolyzes b-series gangliotetraosylceramides more slowly than M-777 enzyme, whereas both enzymes hydrolyse a-series gangliosides and neutral glycosphingolipids to the same extent
-
-
?
additional information
?
-
-
no substrate: N-linked glycoproteins
-
-
?
additional information
?
-
-
no substrate: O-linked glycoproteins
-
-
?
additional information
?
-
-
hardly attacks linkages between monosaccharides and ceramides, i.e. cerebrosides, or between oligosaccharides and diacylglycerol, i.e. glycoglycerolipids
-
-
?
additional information
?
-
-
both rhodococcal EGCases I and II efficiently hydrolyze ganglio-series glycosphingolipids, whereas EGCase I hydrolyzes globo-series-glycosphingolipids much faster than EGCase II. The glycan chain from fucosyl-GM1 can be prepared by using EGCase I. EGCase III stands alone to hydrolyze 6-gala-series glycosphingolipids. All EGCases are not able to hydrolyze sphingomyelin and sulfatide
-
-
?
additional information
?
-
no activity with beta-D-Glc-(1<->1')-ceramide, beta-D-Gal-(1<->1')-ceramide, beta-D-GalNAc-(1->3)-alpha-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide and alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-(alpha-Neu5Ac-(2->3))-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-ceramide
-
-
?
additional information
?
-
-
Fucalpha(1-2)Galbeta(1-3)GalNAcbeta(1-4)(NeuAcalpha(2-3)Galbeta(1-4))Glcbeta(1-1)ceramide is strongly resistant to hydrolysis by the enzyme
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ito, M.; Yamagata, T.
A novel glycosphingolipid-degrading enzyme cleaves the linkage between the oligosaccharide and ceramide of neutral and acidic glycosphingolipids [published erratum appears in J Biol Chem 1987 Feb 5;262(4):1926]
J. Biol. Chem.
261
14278-14282
1986
Rhodococcus sp., Rhodococcus sp. G-74-2
brenda
Ashida, H.; Yamamoto, K.; Kumagai, H.; Tochikura, T.
Purification and characterization of membrane-bound endoglycoceramidase from Corynebacterium sp
Eur. J. Biochem.
205
729-735
1992
Corynebacterium sp.
brenda
Ashida, H.; Tsuji, Y.; Yamamoto, K.; Kumagai, H.; Tochikura, T.
Transglycosylation activity of endoglycoceramidase from Corynebacterium sp
Arch. Biochem. Biophys.
305
559-562
1993
Corynebacterium sp., Corynebacterium sp. A-809
brenda
Ito, M.; Ikegami, Y.; Yamagata, T.
Activator proteins for glycosphingolipid hydrolysis by endoglycoceramidases. Elucidation of biological functions of cell-surface glycosphingolipids in situ by endoglycoceramidases made possible using these activator proteins
J. Biol. Chem.
266
7919-7926
1991
Rhodococcus sp.
brenda
Ito, M.; Yamagata, T.
Purification and characterization of glycosphingolipid-specific endoglycosidases (endoglycoceramidases) from a mutant strain of Rhodococcus sp. Evidence for three molecular species of endoglycoceramidase with different specificities
J. Biol. Chem.
264
9510-9519
1989
Rhodococcus sp.
brenda
Ito, M.; Ikegami, Y.; Omori, A.; Yamagata, T.
Conversion of endoglycoceramidase-activator II by trypsin to the 27.9 kDa polypeptide possessing full activity: purification of activator for endoglycoceramidase by trypsin treatment followed by trypsin-inhibitor agarose column application
J. Biochem.
110
328-332
1991
Rhodococcus sp.
brenda
Ito, M.; Ikegami, Y.; Yamagata, T.
Kinetics of endoglycoceramidase action toward cell-surface glycosphingolipids of erythrocytes
Eur. J. Biochem.
218
645-649
1993
Rhodococcus sp.
brenda
Horibata, Y.; Higashi, H.; Ito, M.
Transglycosylation and reverse hydrolysis reactions of endoglycoceramidase from the jellyfish, Cyanea nozakii
J. Biochem.
130
263-268
2001
Cyanea nozakii
brenda
Horibata, Y.; Okino, N.; Ichinose, S.; Omori, A.; Ito, M.
Purification, characterization, and cDNA cloning of a novel acidic endoglycoceramidase from the jellyfish, Cyanea nozakii
J. Biol. Chem.
275
31297-31304
2000
Cyanea nozakii (Q9GV16), Cyanea nozakii
brenda
Izu, H.; Izumi, Y.; Kurome, Y.; Sano, M.; Kondo, A.; Kato, I.; Ito, M.
Molecular cloning, expression, and sequence analysis of the endoglycoceramidase II gene from Rhodococcus species strain M-777
J. Biol. Chem.
272
19846-19850
1997
Rhodococcus sp. (O33853), Rhodococcus sp.
brenda
Ji, L.; Ito, M.; Zhang, G.; Hirabayashi, Y.; Inokuchi, J.; Yamagata, T.
Effects of endoglycoceramidase or D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol on glucose uptake, glycolysis, and mitochondrial respiration in HL60 cells
Arch. Biochem. Biophys.
359
107-114
1998
Rhodococcus sp.
brenda
Ji, L.; Ito, M.; Zhang, G.; Yamagata, T.
The hydrolysis of cell surface glycosphingolipids by endoglycoceramidase reduces epidermal growth factor receptor phosphorylation in A431 cells
Glycobiology
5
343-350
1995
Rhodococcus sp.
brenda
Mitsutake, S.; Kita, K.; Nakagawa, T.; Ito, M.
Enzymatic synthesis of 14C-glycosphingolipids by reverse hydrolysis reaction of sphingolipid ceramide N-deacylase: detection of endoglycoceramidase activity in a seaflower
J. Biochem.
123
859-863
1998
Condylactis sp., Rhodococcus sp.
brenda
Miura, Y.; Arai, T.; Ohtake, A.; Ito, M.; Yamamoto, K.; Yamagata, T.
Requirement for a different hydrophobic moiety and reliable chromogenic substrate for endo-type glycosylceramidases
Glycobiology
9
957-960
1999
Corynebacterium sp., Rhodococcus sp.
brenda
Sakaguchi, K.; Okino, N.; Izu, H.; Ito, M.
The Glu residue in the conserved Asn-Glu-Pro sequence of endoglycoceramidase is essential for enzymatic activity
Biochem. Biophys. Res. Commun.
260
89-93
1999
Rhodococcus sp., Rhodococcus sp. C9
brenda
Sakaguchi, K.; Okino, N.; Sueyoshi, N.; Izu, H.; Ito, M.
Cloning and expression of gene encoding a novel endoglycoceramidase of Rhodococcus sp. strain C9
J. Biochem.
128
145-152
2000
Rhodococcus sp., Rhodococcus sp. C9
brenda
Yamamoto, K.; Nagano, T.; Kumagai, H.; Okamoto, Y.; Otani, S.
Destruction of cholera toxin receptor on HeLa cell membrane using microbial endoglycoceramidase
Arch. Biochem. Biophys.
328
51-56
1996
Corynebacterium sp.
brenda
Horibata, Y.; Sakaguchi, K.; Okino, N.; Iida, H.; Inagaki, M.; Fujisawa, T.; Hama, Y.; Ito, M.
Unique catabolic pathway of glycosphingolipids in a hydrozoan, Hydra magnipapillata, involving endoglycoceramidase
J. Biol. Chem.
279
33379-33389
2004
Bacillus sp. (in: Bacteria), Hydra vulgaris, Aiptasia sp., Entacmaea sp., Cellana sp., Meretrix sp., Ruditapes sp., Marphysa sp., Cyanea nozakii (Q9GV16), Hydra vulgaris 105
brenda
Korekane, H.; Tsuji, S.; Noura, S.; Ohue, M.; Sasaki, Y.; Imaoka, S.; Miyamoto, Y.
Novel fucogangliosides found in human colon adenocarcinoma tissues by means of glycomic analysis
Anal. Biochem.
364
37-50
2007
Rhodococcus sp.
brenda
Caines, M.E.; Hancock, S.M.; Tarling, C.A.; Wrodnigg, T.M.; Stick, R.V.; Stuetz, A.E.; Vasella, A.; Withers, S.G.; Strynadka, N.C.
The structural basis of glycosidase inhibition by five-membered iminocyclitols: the clan A glycoside hydrolase endoglycoceramidase as a model system
Angew. Chem. Int. Ed. Engl.
46
4474-4476
2007
Rhodococcus sp.
brenda
Xu, X.; Monjusho, H.; Inagaki, M.; Hama, Y.; Yamaguchi, K.; Sakaguchi, K.; Iwamori, M.; Okino, N.; Ito, M.
Fucosyl-GM1a, an endoglycoceramidase-resistant ganglioside of porcine brain
J. Biochem.
141
1-7
2007
Sus scrofa
brenda
Ishibashi, Y.; Nakasone, T.; Kiyohara, M.; Horibata, Y.; Sakaguchi, K.; Hijikata, A.; Ichinose, S.; Omori, A.; Yasui, Y.; Imamura, A.; Ishida, H.; Kiso, M.; Okino, N.; Ito, M.
A novel endoglycoceramidase hydrolyzes oligogalactosylceramides to produce galactooligosaccharides and ceramides
J. Biol. Chem.
282
11386-11396
2007
Rhodococcus equi
brenda
Caines, M.E.; Vaughan, M.D.; Tarling, C.A.; Hancock, S.M.; Warren, R.A.; Withers, S.G.; Strynadka, N.C.
Structural and mechanistic analyses of endo-glycoceramidase II, a membrane-associated family 5 glycosidase in the Apo and GM3 ganglioside-bound forms
J. Biol. Chem.
282
14300-14308
2007
Rhodococcus sp.
brenda
Hancock, S.M.; Tarling, C.A.; Withers, S.G.
High-throughput screening of cell lysates for ganglioside synthesis
Anal. Biochem.
382
48-54
2008
Rhodococcus sp.
brenda
Li, Y.T.; Chou, C.W.; Li, S.C.; Kobayashi, U.; Ishibashi, Y.H.; Ito, M.
Preparation of homogenous oligosaccharide chains from glycosphingolipids
Glycoconj. J.
26
929-933
2009
Rhodococcus sp., Rhodococcus sp. M-750
brenda
Misonou, Y.; Shida, K.; Korekane, H.; Seki, Y.; Noura, S.; Ohue, M.; Miyamoto, Y.
Comprehensive clinico-glycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells
J. Proteome Res.
8
2990-3005
2009
Rhodococcus sp.
brenda
Xu, X.; Horibata, Y.; Inagaki, M.; Hama, Y.; Sakaguchi, K.; Goda, H.M.; Okino, N.; Ito, M.
A novel fucosyl glycosphingolipid of brine shrimp that is highly sensitive to endoglycoceramidase
Glycobiology
19
1446-1451
2009
Rhodococcus sp.
brenda
Ishibashi, Y.; Nagamatsu, Y.; Meyer, S.; Imamura, A.; Ishida, H.; Kiso, M.; Okino, N.; Geyer, R.; Ito, M.
Transglycosylation-based fluorescent labeling of 6-gala series glycolipids by endogalactosylceramidase
Glycobiology
19
797-807
2009
Rhodococcus equi
brenda
Rich, J.R.; Cunningham, A.M.; Gilbert, M.; Withers, S.G.
Glycosphingolipid synthesis employing a combination of recombinant glycosyltransferases and an endoglycoceramidase glycosynthase
Chem. Commun. (Camb. )
47
10806-10808
2011
Rhodococcus sp.
brenda
Karlsson, H.; Halim, A.; Teneberg, S.
Differentiation of glycosphingolipid-derived glycan structural isomers by liquid chromatography/mass spectrometry
Glycobiology
20
1103-1116
2010
Rhodococcus sp.
brenda
Watanabe, T.; Ito, T.; Goda, H.M.; Ishibashi, Y.; Miyamoto, T.; Ikeda, K.; Tagucho, R.; Okino, N.; Ito, M.
Sterylglucoside catabolism in Cryptococcus neoformans with endoglycoceramidase-related protein 2 (EGCrP2), the first steryl-beta-glucosidase identified in fungi
J. Biol. Chem.
290
1005-1019
2015
Cryptococcus neoformans, Cryptococcus neoformans H99
brenda
Ishibashi, Y.; Kobayashi, U.; Hijikata, A.; Sakaguchi, K.; Goda, H.M.; Tamura, T.; Okino, N.; Ito, M.
Preparation and characterization of EGCase I, applicable to the comprehensive analysis of GSLs, using a rhodococcal expression system
J. Lipid Res.
53
2242-2251
2012
Rhodococcus equi
brenda
Albrecht, S.; Vainauskas, S.; Stoeckmann, H.; McManus, C.; Taron, C.H.; Rudd, P.M.
Comprehensive profiling of glycosphingolipid glycans using a novel broad specificity endoglycoceramidase in a high-throughput workflow
Anal. Chem.
88
4795-4802
2016
Rhodococcus triatomae (M2W5L3), Rhodococcus triatomae BKS 15-14 (M2W5L3)
brenda
Ben Bdira, F.; Jiang, J.; Kallemeijn, W.; de Haan, A.; Florea, B.I.; Bleijlevens, B.; Boot, R.; Overkleeft, H.S.; Aerts, J.M.; Ubbink, M.
Hydrophobic interactions contribute to conformational stabilization of endoglycoceramidase II by mechanism-based probes
Biochemistry
55
4823-4835
2016
Rhodococcus sp. (O33853)
brenda
Shen, Y.H.; Tsai, S.T.; Liew, C.Y.; Ni, C.K.
Mass spectrometry-based identification of carbohydrate anomeric configuration to determine the mechanism of glycoside hydrolases
Carbohydr. Res.
476
53-59
2019
Rhodococcus sp. M-777 (O33853)
brenda
Han, Y.B.; Chen, L.Q.; Li, Z.; Tan, Y.M.; Feng, Y.; Yang, G.Y.
Structural insights into the broad substrate specificity of a novel endoglycoceramidase I belonging to a new subfamily of GH5 glycosidases
J. Biol. Chem.
292
4789-4800
2017
Rhodococcus equi (A0A3S5YBC7), Rhodococcus sp. M-777 (O33853), Rhodococcus equi 103S (A0A3S5YBC7)
brenda